← Back to home

MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD)

Clinical trials for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD) explained in plain language.

Never miss a new study

Get alerted when new MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD) trials appear

Sign up with your email to follow new studies for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug trial aims to tame rare neurological disease Flare-Ups

Disease control Ongoing

This study is testing an investigational drug called rozanolixizumab to see if it can prevent relapses and control symptoms in adults with MOG antibody-associated disease (MOG-AD), a rare neurological condition. The trial will involve about 104 participants who will receive eithe…

Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD)

Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control

Last updated Mar 23, 2026 15:16 UTC

MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD)

Get alerted when new MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOG-AD) trials appear

New drug trial aims to tame rare neurological disease Flare-Ups